Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

Ad26.COV2.S vaccine is a replication-incompetent human adenovirus type 26 vector containing the gene sequence that produces SARS-CoV-2 spike protein in a prefusion-stabilized conformation. In a randomized trial involving nearly 40,000 persons, vaccine efficacy was 66% against moderate to severe–crit...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2021-06, Vol.384 (23), p.2187-2201
Hauptverfasser:	Sadoff, Jerald, Gray, Glenda, Vandebosch, An, Cárdenas, Vicky, Shukarev, Georgi, Grinsztejn, Beatriz, Goepfert, Paul A, Truyers, Carla, Fennema, Hein, Spiessens, Bart, Offergeld, Kim, Scheper, Gert, Taylor, Kimberly L, Robb, Merlin L, Treanor, John, Barouch, Dan H, Stoddard, Jeffrey, Ryser, Martin F, Marovich, Mary A, Neuzil, Kathleen M, Corey, Lawrence, Cauwenberghs, Nancy, Tanner, Tamzin, Hardt, Karin, Ruiz-Guiñazú, Javier, Le Gars, Mathieu, Schuitemaker, Hanneke, Van Hoof, Johan, Struyf, Frank, Douoguih, Macaya
Format:	Artikel
Sprache:	eng
Schlagworte:	Ad26COVS1 Adolescent Adult Adverse events Age Aged Asymptomatic Diseases - epidemiology Coronaviruses COVID-19 COVID-19 - epidemiology COVID-19 - mortality COVID-19 - prevention & control COVID-19 vaccines COVID-19 Vaccines - administration & dosage COVID-19 Vaccines - adverse effects COVID-19 Vaccines - immunology Disease transmission Double-Blind Method FDA approval Female Hospitalization - statistics & numerical data Humans Hypotheses Immunogenicity, Vaccine Incidence Infections Male Middle Aged Original Pandemics Patient Acuity Placebos Population Proportional Hazards Models Protein structure Protocol R&D Research & development Safety Severe acute respiratory syndrome coronavirus 2 Spike protein Vaccine efficacy Vaccines Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Ad26.COV2.S vaccine is a replication-incompetent human adenovirus type 26 vector containing the gene sequence that produces SARS-CoV-2 spike protein in a prefusion-stabilized conformation. In a randomized trial involving nearly 40,000 persons, vaccine efficacy was 66% against moderate to severe–critical Covid-19 and 85% against severe–critical Covid-19. Efficacy against the variant first identified in South Africa was 64% against moderate disease and 82% against severe–critical disease.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa2101544